Alkermes (ALKS)

• Market cap: $4.6B
• 1 day: 1.75%
• 5 days: 3.03%
• 1 month: -0.89%
• 3 months: -6.38%
• 6 months: -18.91%
• Year to date: -3.06%
• 1 year: 0.47%
• 5 years: 51.06%
• 10 years: -61.71%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Employees: 1,800

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

41% more call options, than puts

Call options by funds: $15.5M | Put options by funds: $11M

31% more repeat investments, than reductions

Existing positions increased: 154 | Existing positions reduced: 118

2.19% less ownership

Funds ownership: 104.75% [Q1] → 102.56% (-2.19%) [Q2]

5% less funds holding

Funds holding: 369 [Q1] → 350 (-19) [Q2]

14% less capital invested

Capital invested by funds: $5.62B [Q1] → $4.84B (-$785M) [Q2]

24% less first-time investments, than exits

New positions opened: 42 | Existing positions closed: 55

33% less funds holding in top 10

Funds holding in top 10: 6 [Q1] → 4 (-2) [Q2]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35
• Avg. target: $42
• High target: $46

7 analyst ratings

• positive: 4 57%
• neutral: 3 43%
• negative: 0 0%

JP Morgan Jessica Fye	$35	Neutral Maintained	9 Sep 2025
HC Wainwright & Co. Douglas Tsao	$46	Neutral Reiterated	9 Sep 2025
Wells Fargo Benjamin Burnett	$44	Overweight Initiated	3 Sep 2025
RBC Capital Leonid Timashev	$42	Sector Perform Maintained	30 Jul 2025
Needham Ami Fadia	$45	Buy Reiterated	29 Jul 2025